Rectal epithelial apoptosis in familial adenomatous polyposis patients treated with sulindac

Gut

Volumn 45, Issue 6, 1999, Pages 822-828

  Keller, J J ^c   Offerhaus, G J A ^a   Polak, M ^c   Goodman, S N ^a   Zahurak, M L ^a   Hylind, L M ^a   Hamilton, S R ^a   Giardiello, F M ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c NONE

Author keywords

Apoptosis; Familial adenomatous polyposis; Intermediate biomarker; Sulindac; Tumorigenesis

Indexed keywords

PLACEBO; PROTEIN BCL 2; PROTEIN P21; PROTEIN P53; SULINDAC;

ADENOMATOUS POLYP; ADOLESCENT; ADULT; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CARCINOGENESIS; COLON RESECTION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FAMILIAL DISEASE; FEMALE; HISTOPATHOLOGY; HUMAN; INTESTINE CRYPT; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RECTUM ADENOMA; RECTUM BIOPSY; RECTUM MUCOSA; TUMOR REGRESSION;

EID: 0000367992     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.45.6.822     Document Type: Article

References (57)

1. Giardiello FM, Offerhaus GJA, DuBois RN. Role of nonsteroidal drugs in colon cancer prevention. Eur J Cancer 1995;31A:1071-6.
2. Hial V, Demello MC, Horakova Z, et al. Antiproliferative activity of antiinflammatory drugs in two mammalian cell culture cell lines. J Pharmacol Exp Ther 1977;202:446-54.
3. Bayer BM, Beaven MA. Evidence that indomethacin reversibly inhibits cell growth in the G1 phase of the cell cycle. Biochem Pharmacol 1979;28:441-3.
4. Bayer BM, Kruth HS, Vaughan M, et al. Arrest of cultured cells in the G1 phase of the cell cycle by indomethacin. Pharmacol Exp Ther 1979;210:106-11
5. Pollard M, Luckert PH. Indomethacin treatment of rats with dimethylhydrazine-induced intestinal tumors. Cancer Treat Rep 190;64:1323-7.
6. Moorghen M, Ince P, Finney KJ, et al. A protective effect of sulindac against chemically-induced primary colonic tumors in mice. J Pathol 1988;156:341-7.
7. Skinnner SA, Penny AG, O'Brien PE. Sulindac inhibits the rate of growth and development of colon tumors in the rat [abstract]. Gastroenterology 1990;100:A403.
8. Reddy BS, Rao CV, Rivenson A, et al. Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. Carcinogenesis 1993;14:1493-7.
9. Jacoby RF, Marshall DJ, Newton MA, et al. Chemoprevention of spontaneous intestinal adenomas in APC Min mouse model by the nonsteroidal antiinflammatory drug piroxicam. Cancer Res 1996;56:710-15.
10. Thun M, Namboodiri M, Heath C. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991;325:1593-6.
11. Giovannucci E, Rimm EB, Stampfer MJ, et al. Aspirin use and risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 1994;121:241-6.
12. Waddell WR, Loughry RW. Sulindac for polyposis of the colon. J Surg Oncol 1983;24;83-7.
13. Rigau J, Pique JM, Rubio E, et al. Effects of long-term sulinac therapy on colonic polyposis. Ann Intern Med 1991;115:952-4.
14. Labayle D, Fischer D, Vielh P, et al. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 1991;101:635-9.
15. Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993;398:1313-16.
16. Nugent KP, Farmer KCR, Spigelman AD, et al. Randomized controlled clinical trial of sulindac on intestinal polyposis in FAP. Br J Surg 1993;80:1618-19.
17. Lipkin M. Phase 1 and phase 2 proliferative lesions of colonic epithelial cells in diseases leading to colonic cancer. Cancer 1974;34:878-88.
18. Moss SF, Scholes JV, Holt PR. Abnormalities of epithelial apoptosis in multistep colorectal neoplasia demonstrated by terminal deoxyuridine nick end labeling. Dig Dis Sci 1996;41;2238-47.
19. Hall PA, Coates PJ, Ansari B, et al. Regulation of cell number in the mammalian gastrointestinal tract: the importance of apoptosis. J Cell Sci 1994;107:3569-77.
20. Sinicrope FA, Roddey G, McDonell TJ, et al. Increased apoptosis accompanies neoplastic development in the human colorectum. Clin Cancer Res 1996;2:1999-2006.
21. Bedi A, Pasricha PJ, Akhtar AJ, et al. Inhibition of apoptosis during development of colorectal cancer. Cancer Res 1995;55:1811-16.
22. Moss SF, Liu TC, Petrotos A, et al. Inward growth of colonic adenomatous polyps. Gastroenterology 1996;111:1425-32.
23. Krajewski S, Krajewski M, Shabaik A, et al. Immunohistochemical determination of in vivo distribution of Bax, a dominant inhibitor of Bcl-2. Am J Pathol 1994;145:1323-36.
24. Polyak K, Hamilton SR, Vogelstein B, et al. Early alterations of cell-cycle-regulated gene expression in colorectal neoplasia. Am J Pathol 1996;149:381-7.
25. Mosnier J-F, Perret AG, Vindimian M, et al. An immunohistochemical study of the simultaneous expression of Bcl-2 and p53 oncoproteins in epithelial tumors of the colon and rectum. Arch Pathol Lab Med 1996;120:654-9.
26. Baretton GB, Diebold J, Christoforis G. Apoptosis and immunohistochemical bcl-2 expression in colorectal adenomas and carcinomas Cancer 1996;77:255-64.
27. Sinicrope FA, Ruan SB, Cleary KR, et al. hcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res 1995;55:237-41.
28. Mills SJ, Shepherd NA, Hall PA, et al. Proliferative compartment deregulation in the non-neoplastic colonic epithelium of familial adenomatous polyposis. Gut 1995;36:391-4.
29. Pasricha PJ, Bedi A, O'Connor K, et al. The effects of sulinac on colorectal proliferation and apoptosis in familial adenomatous polyposis. Gastroenterology 1996;109:994-8
30. Spagnesi MT, Tonelli F, Dolara P, et al. Rectal proliferation and polyp occurrence in patients with familial adenomatous polyposis after sulindac treatment. Gastroenterology 1994;106:362-6.
31. Mahmoud NN, Boolbol SK, Bilinski RT, et al. APC gene mutation is associated with a dominant-negative effect upon intestinal cell migration. Cancer Res 1997;57:5045-50.
32. Piazza GA, Rahm AK, Finn TS, et al. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrests, and p53 induction. Cancer Res 1997;57:2452-9.
33. Wyllie AH, Kerr JFR, Currie AR. Cell death: the significance of apoptosis. Int Rev Cytol 1980;68:251-306.
34. van de Schepop HAM, de Jong JS, et al. Counting of apoptotic cells: a methodological study in invasive breast cancer. J Clin Pathol Mol Pathol 1996;49:M214-17.
35. Kerr JFR, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972;26:239-57.
36. Slebos RJC, Baas IO, Clement M, et al. Clinical and pathological associations with p53 tumor suppressor gene mutations and expression of p21/waf1/cip1 in colorectal carcinoma. Br J Cancer 1996;74:165-71.
37. Baas IO, Mulder JWR, Offerhaus GJA, et al. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 1994;172:5-12.
38. Giardiello FM, Offerhaus GJA, Tersmette AC, et al. Sulindac-induced regression of colorectal adenomas in familial adenomatous polyposis: evaluation of predictive factors. Gut 1996;38:578-81.
39. SAS Institute Inc. SAS User's Guide: Statistics, Version 5. Cary, NC: SAS Institute Inc., 1985.
40. Piazza G, Rahm A, Pamukcu R, et al. Induction of apoptosis by sulindac metabolites involves a p53 and bcl-2 independent mechanism and does not require cell cycle arrest [abstract]. Gastroenterology 1996;110:A577.
41. Piazza G, Rahm ALK, Krutzch M, et al. Antineoplastic drugs salindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res 1995;55:3110-16.
42. Rao CV, Rivenson A, Simi B, et al. Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal antiinflammatory agent. Cancer Res 1995;55:1464-72.
43. Samaha HS, Kelloff GJ, Steele V, et al. Modulation of apoptosis by sulindac, curcumin, phenylethyl-3-methylcaffeate, and 6-phenylhexyl isothiocyanate: Apoptotic index as biomarker in colon cancer chemoprevention and promotion. Cancer Res 1997;57:1301-5.
44. Shiff SJ, Qiao L, Tsai L-L, et al. Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiesence, and induces apoptosis in HT-29 colon adenocarcinoma cells. J Clin Invest 1995;96:491-503.
45. Chan TA, Morin PJ, Vogelstein B, et al. Mechanisms underlying unsteroidal antiinflammatory drug-mediated apoptosis. Proc Natl Acad Sci USA 1998;95:681-6.
46. Bullions LC, Levine AJ. The role of beta catenin in cell adhesion signal transduction and cancer. Curr Opin Oncol 1998;10:81-7.
47. Hermiston ML, Wong MH, Gordon JI. Forced expression of E-cadherin in the mouse intestinal epithelium slows cell migration and provides evidence for nonautonomous regulation of cell fate in a self-renewing system. Genes Dev 1996;10:985-99.
48. Korinek V, Barker N, Morin PJ, et al. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science 1997;275;1784-7.
49. Morin PJ, Sparks AB, Korinek V, et al. Activation of beta-catenin tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997;275:1787-81.
50. Sparks AB, Morin PJ, Vogelstein B, et al. Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. Cancer Res 1998;58:1130-4.
51. Morin P, Vogelstein B, Kinzler KW. Apoptosis and APC in colorectal tumorigenesis. Proc Natl Acad Sci 1996;93:7950-4.
52. Chan TA, Morin PJ, Vogelstein B, et al. Mechanisms underlying nonsteroidal antiinflammatory drug-induced apoptosis. Proc Natl Acad Sci 1998;95:681-6.
53. Giardiello FM, Spannhake EW, DuBois RN, et al. Prostaglandin levels in human colorectal mucosa: effects of sulindac in patients with familial adenomatous polyposis. Dig Dis Sci 1998;43:311-16.
54. Hanif R, Pittas A, Feng Y, et al. Effects of nonsteroidal antiinflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem Pharmacol 1996;52:237-45
55. Arber N, Kyu-Ho Han E, Sgambata A, et al. A K-ras oncogene increases assistance to sulindac-induced apoptosis in rat enterocytes. Gastroenterology 1997;113:1892-900.
56. Goldberg Y, Nassif H, Pittas A, et al. The anti-proliferative effect of sulindac and sulindac sulfide on HT-29 colon cancer cells: alterations in tumor suppressor and cell cycle-regulatory proteins. Oncogene 1996;12:893-901.
57. Winde G, Schmid KW, Brandt B, et al. Clinical and genomic influence of sulindac on rectal mucosa in familial adenomatous polyposis. Dis Colon Rectum 1997;40:1156-69.